Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.47 USD
-0.17 (-4.67%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.46 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVIR 3.47 -0.17(-4.67%)
Will AVIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVIR
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Other News for AVIR
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update ...
Atea Pharmaceuticals (AVIR) Launches Phase 3 Trial for Hepatitis C Treatment | AVIR Stock News
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing ...
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial